Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
NCITA Vision: Easy access to all forms of imaging

NCITA* have published a Comment article "Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers" in the British Journal of Cancer - https://www.nature.com/articles/s41416-021-01497-5.  This Comment article provides a comprehensive overview of the NCITA infrastructure and its goals to establish standardised protocols and locked-down quality-assured processes for clinical imaging biomarker qualification and a federated research data repository for secure data storage and sharing between multiple study sites.  The infrastructure support is available to clinical researchers in academia and industry through NCITA’s study adoption process.  International partners are also eligible to apply. While cancer imaging studies are a key focus, clinical research studies in other disease areas involving AI algorithm development, training and validation will also be considered for adoption. Through engagement with NHS Trusts, pharmaceutical companies, medical imaging and nuclear medicine companies as well as funding bodies and patient groups, NCITA aims to develop a robust imaging biomarker certification process, to revolutionise the speed and accuracy of cancer diagnosis, tumour classification and patient response to treatment.

*National Cancer Imaging Translational Accelerator (NCITA) is a national UK-wide medical imaging infrastructure which aims to accelerate the standardisation and translation of cancer imaging biomarkers for clinical use.  NCITA is led in Oxford by Professor Geoff Higgins who is part of the NCITA Governance Group, NCITA Engagement Group Chair and project lead for the [18F] FDOPA PET Imaging in Glioma (FIG Trial) and the ARCADIAN study, adopted by NCITA for image repository support.

Read more on NCITA's website

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.